vaccinia-reporter-viruses-for-quantifying-viral-function-at-all

Vaccinia Reporter Viruses for Quantifying Viral Function at All Stages of Gene Expression

Poxviruses are a family of double stranded DNA viruses that include active human pathogens such as monkeypox, molluscum contagiousum, and Contagalo virus. ...

Boston University School of Medicine

We have characterized transcripts synthesized in vivo by bacteriophage T7 RNA polymerase to investigate yeast mRNA processing. T7 transcripts are not capped, consistent with capping being tightly coupled to RNA polymerase II (pol II) transcription. In contrast to higher eukaryotic non-pol II transcripts, yeast T7 transcripts are spliced as well as cleaved and polyadenylated. However, T7 and pol II transcripts are affected differently in cleavage and polyadenylation mutant strains, indicating that pol II may have a role in yeast 3' end formation. T7 transcripts with 3' ends directed by a polyadenylation signal are exported from the nucleus, and this export is dependent on the canonical cleavage and polyadenylation machinery. Importantly, transcripts with T7 terminator-directed 3' ends are unadenylated and predominantly nuclear in wild-type cells. Our results suggest that transcription by pol II is required for neither the nuclear export of an in vivo-transcribed mRNA nor for the retention of transcripts with aberrant 3' ends. Moreover, proper 3' end formation may be necessary and sufficient to promote mRNA export in yeast.

T7 RNA polymerase-directed transcripts are processed in yeast and link 3' end formation to mRNA nuclear export.

Several aspects of eukaryotic mRNA processing are linked to transcription. In Saccharomyces cerevisiae, overexpression of the mRNA export factor Sub2p suppresses the growth defect of hpr1 null cells, yet the protein Hpr1p and the associated THO protein complex are implicated in transcriptional elongation. Indeed, we find that a pool of heat shock HSP104 transcripts are 3'-end truncated in THO complex mutant as well as sub2 mutant backgrounds. Surprisingly, however, this defect can be suppressed by deletion of the 3'-5' exonuclease Rrp6p. This indicates that incomplete RNAs result from nuclear degradation rather than from a failure to efficiently elongate transcription. RNAs that are not degraded are retained at the transcription site in a Rrp6p-dependent manner. Interestingly, the addition of a RRP6 deletion to sub2 or to THO complex mutants shows a strong synthetic growth phenotype, suggesting that the failure to retain and/or degrade defective mRNAs is deleterious. mRNAs produced in the 3'-end processing mutants rna14-3 and rna15-2, as well as an RNA harboring a 3' end generated by a self-cleaving hammerhead ribozyme, are also retained in Rrp6p-dependent transcription site foci. Taken together, our results show that several classes of defective RNPs are subject to a quality control step that impedes release from transcription site foci and suggest that suboptimal messenger ribonucleoprotein assembly leads to RNA degradation by Rrp6p.

Interactions between mRNA export commitment, 3'-end quality control, and nuclear degradation.

Eukaryotic mRNA is processed by enzymes and packaged with proteins within nuclei to generate functional messenger ribonucleoprotein (mRNP) particles. Processing and packaging factors can interact with mRNA cotranscriptionally to form an early mRNP. Erroneous mRNP formation leads to nuclear retention and degradation of the mRNA. It therefore appears that one function of cotranscriptional mRNP assembly is to discard aberrant mRNPs early in their biogenesis. Cotranscriptional mRNP assembly may also enable the transcription machinery to respond to improper mRNP formation.

Early formation of mRNP: license for export or quality control?

To investigate the role of 3' end formation in yeast mRNA export, we replaced the mRNA cleavage and polyadenylation signal with a self-cleaving hammerhead ribozyme element. The resulting RNA is unadenylated and accumulates near its site of synthesis. Nonetheless, a significant fraction of this RNA reaches the cytoplasm. Nuclear accumulation was relieved by insertion of a stretch of DNA-encoded adenosine residues immediately upstream of the ribozyme element (a synthetic A tail). This indicates that a 3' stretch of adenosines can promote export, independently of cleavage and polyadenylation. We further show that a synthetic A tail-containing RNA is unaffected in 3' end formation mutant strains, in which a normally cleaved and polyadenylated RNA accumulates within nuclei. Our results support a model in which a polyA tail contributes to efficient mRNA progression away from the gene, most likely through the action of the yeast polyA-tail binding protein Pab1p.

A synthetic A tail rescues yeast nuclear accumulation of a ribozyme-terminated transcript.

Nonsense-mediated decay (NMD) is a eukaryotic regulatory process that degrades mRNAs with premature termination codons (PTCs). Although NMD is a translation-dependent process, there is evidence from mammalian systems that PTC recognition and mRNA degradation takes place in association with nuclei. Consistent with this notion, degradation of mammalian PTC-containing mRNAs occurs when they are bound by the cap binding complex (CBC) during a "pioneer" round of translation. Moreover, there are reports indicating that a PTC can trigger other nuclear events such as alternative splicing, abnormal 3' end processing, and accumulation of pre-mRNA at transcription sites. To examine whether a PTC can elicit similar nuclear events in yeast, we used RNA export-defective mutants to sequester mRNAs within nuclei. The results indicate that nuclear PTC-containing yeast RNAs are NMD insensitive. We also observed by fluorescent in situ hybridization that there was no PTC effect on mRNA accumulated at the site of transcription. Finally, we show that yeast NMD occurs minimally if at all on CBC-bound transcripts, arguing against a CBC-mediated pioneer round of translation in yeast. The data taken together indicate that there are no direct consequences of a PTC within the yeast nucleus.

Nonsense-mediated decay does not occur within the yeast nucleus.

Multiple studies indicate that mRNA processing defects cause mRNAs to accumulate in discrete nuclear foci or dots, in mammalian cells as well as yeast. To investigate this phenomenon, we have studied a series of GAL reporter constructs integrated into the yeast genome adjacent to an array of TetR-GFP-bound TetO sites. mRNA within dots is predominantly post-transcriptional, and dots are adjacent to but distinct from their transcription site. These reporter genes also localize to the nuclear periphery upon gene induction, like their endogenous GAL counterparts. Surprisingly, this peripheral localization persists long after transcriptional shutoff, and there is a comparable persistence of the RNA in the dots. Moreover, dot disappearance and gene delocalization from the nuclear periphery occur with similar kinetics after transcriptional shutoff. Both kinetics depend in turn on reporter gene 3'-end formation signals. Our experiments indicate that gene association with the nuclear periphery does not require ongoing transcription and suggest that the mRNPs within dots may make a major contribution to the gene-nuclear periphery tether.

3'-end formation signals modulate the association of genes with the nuclear periphery as well as mRNP dot formation.

TREM-1 (triggering receptor expressed on myeloid cells-1) is an orphan immunoreceptor expressed on monocytes, macrophages, and neutrophils. TREM-1 associates with and signals via the adapter protein DAP12/TYROBP, which contains an ITAM. TREM-1 activation by receptor cross-linking has been shown to be proinflammatory and to amplify some cellular responses to TLR ligands such as bacterial LPS. To investigate the cellular consequences of TREM-1 activation, we have characterized global gene expression changes in human monocytes in response to TREM-1 cross-linking in comparison to and combined with LPS. Both TREM-1 activation and LPS up-regulate chemokines, cytokines, matrix metalloproteases, and PTGS/COX2, consistent with a core inflammatory response. However, other immunomodulatory factors are selectively induced, including SPP1 and CSF1 (i.e., M-CSF) by TREM-1 activation and IL-23 and CSF3 (i.e., G-CSF) by LPS. Additionally, cross-talk between TREM-1 activation and LPS occurs on multiple levels. Although synergy in GM-CSF protein production is reflected in commensurate mRNA abundance, comparable synergy in IL-1beta protein production is not. TREM-1 activation also attenuates the induction of some LPS target genes, including those that encode IL-12 cytokine family subunits. Where tested, positive TREM-1 outputs are greatly reduced by the PI3K inhibitor wortmannin, whereas this attenuation is largely PI3K independent. These experiments provide a detailed analysis of the cellular consequences of TREM-1 activation and highlight the complexity in signal integration between ITAM- and TLR-mediated signaling.

Innate immune responses to TREM-1 activation: overlap, divergence, and positive and negative cross-talk with bacterial lipopolysaccharide.

To investigate the expression and function of triggering receptor expressed on myeloid cells-1 (TREM-1) in the synovium of human RA patients as well as the level of soluble TREM-1 in the plasma of RA patients.

TREM-1 expression is increased in the synovium of rheumatoid arthritis patients and induces the expression of pro-inflammatory cytokines.

&#x75D8;&#x82D7;&#x75C5;&#x6BD2;&#x662F; Poxviridae&#xFF0C;&#x4E00;&#x4E2A;&#x5BB6;&#x5EAD;&#x7684;&#x75C5;&#x6BD2;&#xFF0C;&#x5176;&#x4E2D;&#x5305;&#x62EC;&#x4EBA;&#x7C7B;&#x7684;&#x75C5;&#x539F;&#x4F53; (&#x5929;&#x82B1;) &#x5929;&#x82B1;&#x548C;&#x7334;&#x75D8;&#x7684;&#x539F;&#x578B;&#x6B63;&#x75D8;&#x75C5;&#x6BD2;&#x3002;&#x75C5;&#x6BD2;&#x6027;&#x7684;&#x6838;&#x5FC3;&#x804C;&#x80FD;&#x4E4B;&#x4E00; orthopoxviruses&#xFF0C;&#x4FDD;&#x5B88;&#xFF0C;&#x56E0;&#x6B64;&#x75D8;&#x82D7;&#x7ECF;&#x5E38;&#x7528;&#x4E8E;&#x75D8;&#x75C5;&#x6BD2;&#x751F;&#x7269;&#x5B66;&#x548C;&#x5C4F;&#x5E55;&#x4E0A;&#x7684;&#x65B0;&#x578B;&#x6297;&#x75C5;&#x6BD2;&#x5316;&#x5408;&#x7269;&#x7684;&#x7814;&#x7A76;&#x3002;&#x6211;&#x4EEC;&#x5728;&#x8FD9;&#x91CC;&#x4ECB;&#x7ECD;&#x7684;&#x4E00;&#x7CFB;&#x5217;&#x524D;&#x6240;&#x672A;&#x6709;&#x7684;&#x51B3;&#x8BAE;&#x63D0;&#x4F9B;&#x7528;&#x4E8E;&#x8DDF;&#x8E2A;&#x75C5;&#x6BD2;&#x529F;&#x80FD;&#x7684;&#x8367;&#x5149;&#x86CB;&#x767D;&#x4E3A;&#x57FA;&#x7840;&#x7684;&#x8BB0;&#x8005;&#x75D8;&#x82D7;&#x75C5;&#x6BD2;&#x7684;&#x53D1;&#x5C55;&#x3002;&#x8BB0;&#x8005;&#x75C5;&#x6BD2;&#x5206;&#x4E3A;&#x4E24;&#x7EC4;&#xFF1A; &#xFF08;1&#xFF09; &#x5355;&#x4E2A;&#x8BB0;&#x8005;&#x75C5;&#x6BD2;&#x5229;&#x7528;&#x6682;&#x65F6;&#x7684;&#x89C4;&#x7BA1;&#x521D;&#x3001; &#x4E2D;&#x7EA7;&#x3001; &#x6216;&#x665A;&#x75C5;&#x6BD2;&#x6027;&#x7684;&#x4FC3;&#x8FDB;&#x8005; &#xFF1B;(2) multi-reporter &#x75C5;&#x6BD2;&#xFF0C;&#x6682;&#x65F6;&#x5229;&#x7528;&#x591A;&#x4E2A;&#x89C4;&#x8303;&#x5BA3;&#x4F20;&#x5458;&#x548C;&#x3002;&#x542F;&#x52A8;&#x5B50;&#x548C;&#x8BB0;&#x8005;&#x7684;&#x7EC4;&#x5408;&#x88AB;&#x9009;&#xFF0C;&#x4EA7;&#x751F;&#x4E86;&#x9AD8;&#x9636;&#x6BB5;&#x7279;&#x5B9A;&#x75C5;&#x6BD2;&#x6027;&#x4EA7;&#x51FA;&#x4E3A;&#x80CC;&#x666F;&#x4FE1;&#x53F7;&#x3002;&#x6211;&#x4EEC;&#x4E3A;&#x8FD9;&#x4E9B;&#x75C5;&#x6BD2;&#x5982;&#x4F55;&#x53EF;&#x4EE5;&#x7528;&#x725B;&#x75D8;&#x529F;&#x80FD;&#x548C;&#x836F;&#x7269;&#x884C;&#x52A8;&#x8FC5;&#x901F;&#x548C;&#x51C6;&#x786E;&#x5730;&#x76D1;&#x6D4B;&#x63D0;&#x4F9B;&#x7684;&#x4F8B;&#x5B50;&#x3002;

&#x75C5;&#x6BD2;&#x6027;&#x529F;&#x80FD;&#x5FEB;&#x901F;&#x3001; &#x9AD8;&#x5185;&#x5BB9;&#x5206;&#x6790;&#x8BB0;&#x8005;&#x75D8;&#x82D7;&#x75C5;&#x6BD2;&#x7684;&#x57FA;&#x56E0;&#x8868;&#x8FBE;&#x7684;&#x6240;&#x6709;&#x9636;&#x6BB5;&#x7684;&#x53D1;&#x5C55;&#x3002;

Vaccinia virus is the prototypical orthopoxvirus of Poxviridae, a family of viruses that includes the human pathogens Variola (smallpox) and Monkeypox. Core viral functions are conserved among orthopoxviruses, and consequently Vaccinia is routinely used to study poxvirus biology and screen for novel antiviral compounds. Here we describe the development of a series of fluorescent protein-based reporter Vaccinia viruses that provide unprecedented resolution for tracking viral function. The reporter viruses are divided into two sets: (1) single reporter viruses that utilize temporally regulated early, intermediate, or late viral promoters; and (2) multi-reporter viruses that utilize multiple temporally regulated promoters. Promoter and reporter combinations were chosen that yielded high signal-to-background for stage-specific viral outputs. We provide examples for how these viruses can be used in the rapid and accurate monitoring of Vaccinia function and drug action.

Development of Vaccinia reporter viruses for rapid, high content analysis of viral function at all stages of gene expression.

Virus de la vaccine est le prototype de orthopoxvirus Poxviridae, une famille de virus qui comprend les agents pathog&#xE8;nes humains variolique (la variole) et du singe. De base des fonctions virales sont conserv&#xE9;es chez les orthopoxvirus, et par cons&#xE9;quent la vaccine est couramment utilis&#xE9;e pour &#xE9;tudier la biologie et de poxvirus &#xE9;cran pour de nouveaux compos&#xE9;s antiviraux. Nous d&#xE9;crivons ici le d&#xE9;veloppement d&#x26;#39;une s&#xE9;rie de fluorescents &#xE0; base de prot&#xE9;ines virus de la vaccine journaliste qui fournissent une r&#xE9;solution sans pr&#xE9;c&#xE9;dent pour le suivi de la fonction virale. Les virus rapporteurs sont divis&#xE9;s en deux ensembles: (1) virus seul journaliste qui utilisent temporairement r&#xE9;glement&#xE9;e pr&#xE9;coces, interm&#xE9;diaires, ou &#xE0; la fin des promoteurs viraux, et (2) multi-rapporteurs virus qui utilisent plusieurs promoteurs temporellement r&#xE9;glement&#xE9;s. Promoteur des combinaisons et journaliste ont &#xE9;t&#xE9; choisis qui a produit un rapport signal-&#xE0;-fond pour la sc&#xE8;ne-sp&#xE9;cifiques sorties virales. Nous fournissons des exemples de la fa&#xE7;on dont ces virus peuvent &#xEA;tre utilis&#xE9;s dans le suivi rapide et pr&#xE9;cis de la fonction vaccine et l&#x26;#39;action des m&#xE9;dicaments.

D&#xE9;veloppement des virus vaccine Reporter pour l&#x26;#39;analyse rapide et &#xE0; haute teneur en de la fonction virale &#xE0; toutes les &#xE9;tapes de l&#x26;#39;expression g&#xE9;n&#xE9;tique

Vaccinia-Virus ist die prototypische Orthopoxvirus Poxviridae, eine Familie von Viren, die die menschliche Krankheitserreger Variola (Pocken) und Monkeypox enth&auml;lt. Virale Kernfunktionen sind unter Orthopoxviruses konserviert, und folglich Vaccinia wird routinem&auml;&szlig;ig verwendet, um die Pockenviren Biologie und Bildschirm f&uuml;r neuartige antivirale Substanzen zu studieren. Hier beschreiben wir die Entwicklung einer Reihe von fluoreszierenden Protein-basierte Reporter Vaccinia-Viren, die bis dahin unerreichter Aufl&ouml;sung bieten f&uuml;r die Verfolgung von viralen Funktion. Die Reporter-Viren sind in zwei Gruppen unterteilt: (1) einzelne Reporter-Viren, die zeitlich nutzen geregelt fr&uuml;he, mittlere oder sp&auml;te virale Promotoren; und (2) multi-reporter Viren, die mehrere zeitlich nutzen reguliert F&ouml;rderer. Projekttr&auml;ger und Reporter-Kombinationen wurden ausgew&auml;hlt, dass das hohen Signal-zu-Hintergrund f&uuml;r B&uuml;hne-spezifische virale Ausg&auml;nge ergab. Wir bieten Beispiele wie diese Viren in die schnelle und genaue &Uuml;berwachung der Vaccinia-Funktion und Drogen-Aktion verwendet werden k&ouml;nnen.

Entwicklung von Vaccinia Reporter Viren f&uuml;r schnelle, hohe Inhaltsanalyse der viral-Funktion auf allen Stufen der Genexpression.

Vaccinia virus &egrave; il prototipo orthopoxvirus di Poxviridae, una famiglia di virus che include i patogeni umani Variola (vaiolo) e vaiolo delle scimmie. Nucleo virale funzioni sono conservate tra i orthopoxviruses, e di conseguenza Vaccinia viene utilizzato regolarmente per studiare biologia poxvirus e schermo per nuovi composti antivirali. Qui descriviamo lo sviluppo di una serie di virus di Vaccinia reporter basati su proteine fluorescenti che forniscono la risoluzione senza precedenti per il rilevamento delle funzione virale. Il virus di reporter sono divisi in due gruppi: virus (1) unico reporter che utilizzano temporaneamente regolato promotori virale precoce, intermediate o tardiva; e (2) multi-reporter virus che utilizzano pi&ugrave; temporalmente regolamentato promotori. Combinazioni di promotore e reporter sono stati scelti che ha reso alto segnale a sfondo per uscite virali specifici di fase. Forniamo esempi per come questi virus possono essere utilizzati nel monitoraggio rapido e preciso di azione funzione e droga Vaccinia.

Sviluppo del virus di Vaccinia reporter per rapida, alta analisi del contenuto della funzione virale in tutte le fasi dell&#39;espressione genica.

&#x30EF;&#x30AF;&#x30B7;&#x30CB;&#x30A2;&#x30A6;&#x30A4;&#x30EB;&#x30B9;&#x306F;&#x3001;&#x30DD;&#x30C3;&#x30AF;&#x30B9;&#x30A6;&#x30A4;&#x30EB;&#x30B9;&#x79D1;&#x306E;&#x5178;&#x578B;&#x30AA;&#x30EB;&#x30BD;&#x3001;&#x30D2;&#x30C8;&#x75C5;&#x539F;&#x4F53;&#x75D8;&#x7621;&#xFF08;&#x5929;&#x7136;&#x75D8;&#xFF09;&#x3084;&#x30B5;&#x30EB;&#x3092;&#x542B;&#x3080;&#x30A6;&#x30A4;&#x30EB;&#x30B9;&#x306E;&#x30D5;&#x30A1;&#x30DF;&#x30EA;&#x30FC;&#x3067;&#x3059;&#x3002;&#x30B3;&#x30A2;&#x30A6;&#x30A4;&#x30EB;&#x30B9;&#x6A5F;&#x80FD;&#x306F;&#x3001;orthopoxviruses&#x9593;&#x3067;&#x4FDD;&#x5B58;&#x3055;&#x308C;&#x3001;&#x305D;&#x306E;&#x7D50;&#x679C;&#x3001;&#x30EF;&#x30AF;&#x304C;&#x65E5;&#x5E38;&#x30DD;&#x30C3;&#x30AF;&#x30B9;&#x30A6;&#x30A4;&#x30EB;&#x30B9;&#x306E;&#x751F;&#x7269;&#x5B66;&#x304A;&#x3088;&#x3073;&#x65B0;&#x898F;&#x6297;&#x30A6;&#x30A4;&#x30EB;&#x30B9;&#x5316;&#x5408;&#x7269;&#x306E;&#x30B9;&#x30AF;&#x30EA;&#x30FC;&#x30CB;&#x30F3;&#x30B0;&#x3092;&#x7814;&#x7A76;&#x3059;&#x308B;&#x305F;&#x3081;&#x306B;&#x4F7F;&#x7528;&#x3055;&#x308C;&#x3066;&#x3044;&#x307E;&#x3059;&#x3002;&#x3053;&#x3053;&#x3067;&#x306F;&#x3001;&#x30A6;&#x30A4;&#x30EB;&#x30B9;&#x306E;&#x6A5F;&#x80FD;&#x3092;&#x8FFD;&#x8DE1;&#x3059;&#x308B;&#x305F;&#x3081;&#x306E;&#x524D;&#x4F8B;&#x306E;&#x306A;&#x3044;&#x89E3;&#x50CF;&#x5EA6;&#x3092;&#x63D0;&#x4F9B;&#x3057;&#x3066;&#x86CD;&#x5149;&#x30BF;&#x30F3;&#x30D1;&#x30AF;&#x8CEA;&#x30D9;&#x30FC;&#x30B9;&#x306E;&#x30EC;&#x30DD;&#x30FC;&#x30BF;&#x30FC;&#x30EF;&#x30AF;&#x30B7;&#x30CB;&#x30A2;&#x30A6;&#x30A4;&#x30EB;&#x30B9;&#x306E;&#x30B7;&#x30EA;&#x30FC;&#x30BA;&#x306E;&#x958B;&#x767A;&#x306B;&#x3064;&#x3044;&#x3066;&#x8AAC;&#x660E;&#x3057;&#x307E;&#x3059;&#x3002; &#xFF08;1&#xFF09;&#x3092;&#x5229;&#x7528;&#x3057;&#x3001;&#x5358;&#x4E00;&#x306E;&#x30EC;&#x30DD;&#x30FC;&#x30BF;&#x30FC;&#x30A6;&#x30A4;&#x30EB;&#x30B9;&#x306F;&#x4E00;&#x6642;&#x7684;&#x306B;&#x65E9;&#x304F;&#x3001;&#x4E2D;&#x9593;&#x3001;&#x307E;&#x305F;&#x306F;&#x5F8C;&#x671F;&#x30A6;&#x30A4;&#x30EB;&#x30B9;&#x30D7;&#x30ED;&#x30E2;&#x30FC;&#x30BF;&#x30FC;&#x3092;&#x8ABF;&#x7BC0;&#x3057;&#x3001;&#xFF08;2&#xFF09;&#x8907;&#x6570;&#x306E;&#x6642;&#x9593;&#x7684;&#x8ABF;&#x7BC0;&#x30D7;&#x30ED;&#x30E2;&#x30FC;&#x30BF;&#x30FC;&#x3092;&#x5229;&#x7528;&#x3057;&#x305F;&#x30DE;&#x30EB;&#x30C1;&#x30EC;&#x30DD;&#x30FC;&#x30BF;&#x30FC;&#x30A6;&#x30A4;&#x30EB;&#x30B9;&#xFF1A;&#x30EC;&#x30DD;&#x30FC;&#x30BF;&#x30FC;&#x30A6;&#x30A4;&#x30EB;&#x30B9;&#x306F;&#x3001;&#x4E8C;&#x7D44;&#x306B;&#x5206;&#x304B;&#x308C;&#x3066;&#x3044;&#x307E;&#x3059;&#x3002;&#x30D7;&#x30ED;&#x30E2;&#x30FC;&#x30BF;&#x30FC;&#x3068;&#x30EC;&#x30DD;&#x30FC;&#x30BF;&#x30FC;&#x306E;&#x7D44;&#x307F;&#x5408;&#x308F;&#x305B;&#x306F;&#x3001;&#x30B9;&#x30C6;&#x30FC;&#x30B8;&#x56FA;&#x6709;&#x306E;&#x30A6;&#x30A4;&#x30EB;&#x30B9;&#x306E;&#x51FA;&#x529B;&#x306E;&#x9AD8;&#x3044;&#x4FE1;&#x53F7;&#x5BFE;&#x30D0;&#x30C3;&#x30AF;&#x30B0;&#x30E9;&#x30A6;&#x30F3;&#x30C9;&#x3092;&#x3082;&#x305F;&#x3089;&#x3057;&#x305F;&#x305D;&#x306E;&#x9078;&#x3070;&#x308C;&#x307E;&#x3057;&#x305F;&#x3002;&#x6211;&#x3005;&#x306F;&#x3001;&#x3053;&#x308C;&#x3089;&#x306E;&#x30A6;&#x30A4;&#x30EB;&#x30B9;&#x306F;&#x3001;&#x30EF;&#x30AF;&#x30B7;&#x30CB;&#x30A2;&#x30A6;&#x30A4;&#x30EB;&#x30B9;&#x6A5F;&#x80FD;&#x3068;&#x85AC;&#x7269;&#x4F5C;&#x7528;&#x306E;&#x8FC5;&#x901F;&#x304B;&#x3064;&#x6B63;&#x78BA;&#x306A;&#x30E2;&#x30CB;&#x30BF;&#x30EA;&#x30F3;&#x30B0;&#x306B;&#x4F7F;&#x7528;&#x3059;&#x308B;&#x3053;&#x3068;&#x304C;&#x3067;&#x304D;&#x308B;&#x65B9;&#x6CD5;&#x306E;&#x4F8B;&#x3092;&#x63D0;&#x4F9B;&#x3057;&#x3066;&#x3044;&#x307E;&#x3059;&#x3002;

&#x907A;&#x4F1D;&#x5B50;&#x767A;&#x73FE;&#x306E;&#x3059;&#x3079;&#x3066;&#x306E;&#x6BB5;&#x968E;&#x3067;&#x30A6;&#x30A4;&#x30EB;&#x30B9;&#x6A5F;&#x80FD;&#x306E;&#x8FC5;&#x901F;&#x3001;&#x30CF;&#x30A4;&#x30B3;&#x30F3;&#x30C6;&#x30F3;&#x30C8;&#x5206;&#x6790;&#x306E;&#x305F;&#x3081;&#x306E;&#x30EF;&#x30AF;&#x30EC;&#x30DD;&#x30FC;&#x30BF;&#x30FC;&#x30A6;&#x30A4;&#x30EB;&#x30B9;&#x306E;&#x958B;&#x767A;

Vaccinia &#xBC14;&#xC774;&#xB7EC;&#xC2A4;&#xB294; Poxviridae, Variola (&#xCC9C;&#xC5F0;&#xB450;) &#xBC0F; Monkeypox &#xC778;&#xAC04;&#xC758; &#xBCD1;&#xC6D0; &#xCCB4;&#xB97C; &#xD3EC;&#xD568; &#xD558;&#xB294; &#xBC14;&#xC774;&#xB7EC;&#xC2A4;&#xC758; &#xAC00;&#xC871;&#xC758; &#xC6D0;&#xD615; orthopoxvirus. Orthopoxviruses, &#xAC00;&#xC6B4;&#xB370; &#xCF54;&#xC5B4; &#xBC14;&#xC774;&#xB7EC;&#xC2A4; &#xC131; &#xAE30;&#xB2A5;&#xC744; &#xBCF4;&#xC874; &#xB429;&#xB2C8;&#xB2E4; &#xBC0F; &#xB530;&#xB77C;&#xC11C; Vaccinia &#xC815;&#xAE30;&#xC801;&#xC73C;&#xB85C; &#xC18C;&#xC124; &#xD56D; &#xBC14;&#xC774;&#xB7EC;&#xC2A4; &#xD654;&#xD569;&#xBB3C;&#xC5D0; &#xB300; &#xD55C; &#xD654;&#xBA74; poxvirus &#xC0DD;&#xBB3C;&#xD559;&#xC744; &#xACF5;&#xBD80; &#xD558; &#xACE0; &#xC0AC;&#xC6A9;. &#xC5EC;&#xAE30; &#xC6B0;&#xB9AC;&#xAC00; &#xBC14;&#xC774;&#xB7EC;&#xC2A4; &#xC131; &#xAE30;&#xB2A5;&#xC744; &#xCD94;&#xC801; &#xD558;&#xAE30; &#xC704;&#xD55C; &#xC804;&#xB840; &#xC5C6;&#xB294; &#xD574;&#xC0C1;&#xB3C4; &#xC81C;&#xACF5; &#xD558;&#xB294; &#xD615;&#xAD11; &#xB2E8;&#xBC31;&#xC9C8; &#xAE30;&#xBC18; &#xAE30;&#xC790; Vaccinia &#xBC14;&#xC774;&#xB7EC;&#xC2A4;&#xC758; &#xC77C;&#xB828;&#xC758; &#xAC1C;&#xBC1C;&#xC744; &#xC124;&#xBA85; &#xD569;&#xB2C8;&#xB2E4;. &#xAE30;&#xC790; &#xBC14;&#xC774;&#xB7EC;&#xC2A4; &#xB450; &#xC138;&#xD2B8;&#xB85C; &#xB098;&#xB269;&#xB2C8;&#xB2E4;: &#xC77C;&#xC2DC;&#xC801;&#xC73C;&#xB85C; &#xD65C;&#xC6A9; (1) &#xB2E8;&#xC77C; &#xAE30;&#xC790; &#xBC14;&#xC774;&#xB7EC;&#xC2A4; &#xADDC;&#xC81C; &#xCD08;&#xAE30;, &#xC911;&#xAC04;, &#xB610;&#xB294; &#xB2A6;&#xAC8C; &#xBC14;&#xC774;&#xB7EC;&#xC2A4; &#xC131; &#xBC1C;&#xAE30;&#xC778;; &#xADF8;&#xB9AC;&#xACE0; &#xC77C;&#xC2DC;&#xC801;&#xC73C;&#xB85C; &#xC5EC;&#xB7EC; &#xD65C;&#xC6A9; (2) multi-reporter &#xBC14;&#xC774;&#xB7EC;&#xC2A4; &#xADDC;&#xC81C; &#xBC1C;&#xAE30;&#xC778;. &#xBC1C;&#xAE30;&#xC778; &#xBC0F; &#xAE30;&#xC790; &#xC870;&#xD569; &#xD558;&#xB294; &#xB192;&#xC740; &#xC2E0;&#xD638;--&#xBC30;&#xACBD;&#xC73C;&#xB85C; &#xBB34;&#xB300; &#xAD00;&#xB828; &#xBC14;&#xC774;&#xB7EC;&#xC2A4; &#xCD9C;&#xB825;&#xC5D0; &#xB300; &#xD55C; &#xAD74;&#xBCF5; &#xC120;&#xC815; &#xB410;&#xB2E4;. &#xC6B0;&#xB9AC;&#xAC00; &#xC5B4;&#xB5BB;&#xAC8C; &#xC774;&#xB7EC;&#xD55C; &#xBC14;&#xC774;&#xB7EC;&#xC2A4; Vaccinia &#xD568;&#xC218; &#xBC0F; &#xC57D;&#xBB3C; &#xC791;&#xC5C5;&#xC744; &#xC2E0;&#xC18D; &#xD558; &#xACE0; &#xC815;&#xD655;&#xD55C; &#xBAA8;&#xB2C8;&#xD130;&#xB9C1;&#xC5D0; &#xC0AC;&#xC6A9;&#xD560; &#xC218;&#xC5D0; &#xB300; &#xD55C; &#xC608;&#xC81C;&#xB97C; &#xC81C;&#xACF5; &#xD569;&#xB2C8;&#xB2E4;.

&#xC720;&#xC804;&#xC790; &#xBC1C;&#xD604;&#xC758; &#xBAA8;&#xB4E0; &#xB2E8;&#xACC4;&#xC5D0;&#xC11C; &#xBC14;&#xC774;&#xB7EC;&#xC2A4; &#xC131; &#xD568;&#xC218;&#xC758; &#xC2E0;&#xC18D; &#xD558; &#xAC8C;, &#xB192;&#xC740; &#xCF58;&#xD150;&#xCE20; &#xBD84;&#xC11D; Vaccinia &#xAE30;&#xC790; &#xBC14;&#xC774;&#xB7EC;&#xC2A4;&#xC758; &#xAC1C;&#xBC1C;.

El virus vaccinia es el prototipo de ortopoxvirus Poxviridae, una familia de virus que incluye a los pat&#xF3;genos humanos Variola (viruela) y la viruela del simio. Principales funciones virales se conservan entre los ortopoxvirus, y por lo tanto la vacuna se utiliza rutinariamente para estudiar la biolog&#xED;a de virus de la viruela y la pantalla de nuevos compuestos antivirales. Aqu&#xED; se describe el desarrollo de una serie de fluorescentes a base de prote&#xED;na de los virus vaccinia reportero que proporcionan una resoluci&#xF3;n sin precedentes para el seguimiento de la funci&#xF3;n viral. Los virus de la periodista se dividen en dos grupos: (1) los virus que utilizan un solo reportero regulado temporalmente promotores virales precoces, intermedios o finales, y (2) de varios reporteros virus que utilizan m&#xFA;ltiples promotores regulado temporalmente. Combinaciones de promotor y el reportero se eligieron que produjo una alta relaci&#xF3;n se&#xF1;al-a-fondo para etapa espec&#xED;fica de productos virales. Se proporcionan ejemplos de c&#xF3;mo estos virus pueden ser utilizados en el control r&#xE1;pido y preciso de la funci&#xF3;n vaccinia y la acci&#xF3;n del f&#xE1;rmaco.

Desarrollo de los virus vaccinia reportero para el an&#xE1;lisis r&#xE1;pido, alto contenido de la funci&#xF3;n viral en todas las etapas de la Expresi&#xF3;n G&#xE9;nica

Orthopoxviruses &#x5305;&#x62EC;&#x539F;&#x578B;&#x75D8;&#x82D7;&#x75C5;&#x6BD2;&#x3001; &#x65B0;&#x5174;&#x4F20;&#x67D3;&#x75C5;&#x4EE3;&#x7406;&#x7334;&#x75D8;&#x75C5;&#x6BD2;&#xFF0C;&#x4EE5;&#x53CA;&#x6F5C;&#x5728;&#x7684; biothreat &#x5929;&#x82B1;&#x75C5;&#x6BD2; (&#x5929;&#x82B1;&#x7684;&#x75C5;&#x6E90;&#x4F53;&#xFF09;&#x3002;&#x76EE;&#x524D;&#x662F;&#x6CA1;&#x6709;&#x7F8E;&#x56FD; FDA &#x6279;&#x51C6;&#x7684;&#x836F;&#x7269; orthopoxviruses &#x611F;&#x67D3;&#x4EBA;&#x7C7B;&#x3002;&#x6211;&#x4EEC;&#x5BF9;&#x75D8;&#x82D7;&#x75C5;&#x6BD2;&#x6D3B;&#x6027;&#x4E0E;&#x7504;&#x522B;&#x65B0;&#x652F;&#x67B6;&#x591A;&#x6837;&#x6027;&#x5BFC;&#x5411;&#x7684;&#x5408;&#x6210;&#x5E93;&#x3002;&#x6B64;&#x5C4F;&#x5E55;&#x786E;&#x5B9A;&#x975E;&#x6838;&#x82F7;&#x7C7B;&#x6A21;&#x62DF;&#x963B;&#x6B62; postreplicative &#x665A;&#x671F;&#x57FA;&#x56E0;&#x7684;&#x8868;&#x8FBE;&#x3002;&#x75C5;&#x6BD2;&#x57FA;&#x56E0;&#x7EC4;&#x590D;&#x5236;&#x5E76;&#x6CA1;&#x6709;&#x53D7;&#x5230;&#x5F71;&#x54CD;&#xFF0C;&#x53EF;&#x4EE5;&#x665A;&#x5728;&#x611F;&#x67D3;&#x5F15;&#x8D77;&#x548C;&#x4FDD;&#x6301;&#x836F;&#x7269;&#x53D6;&#x6D88;&#x540E;&#x6291;&#x5236;&#x4F5C;&#x7528;&#x3002;&#x8010;&#x836F;&#x75C5;&#x6BD2;&#x6D4B;&#x5E8F;&#x63ED;&#x793A;&#x9884;&#x8BA1;&#x5728;&#x8FB9;&#x7F18;&#x7684;&#x9AD8;&#x5EA6;&#x4FDD;&#x5B88;&#x7684;&#x75C5;&#x6BD2; RNA &#x805A;&#x5408;&#x9176;&#x5927;&#x4E9A;&#x57FA;&#x4E0A;&#x7684;&#x7A81;&#x53D8;&#x3002;&#x4E0E;&#x6B64;&#x76F8;&#x4E00;&#x81F4;&#xFF0C;&#x590D;&#x5408;&#x4E86;&#x5BF9; orthopoxviruses &#x4F53;&#x5916;&#x7684;&#x5E7F;&#x8C31;&#x6D3B;&#x6027;&#x3002;&#x8FD9;&#x4E9B;&#x7814;&#x7A76;&#x7ED3;&#x679C;&#x8868;&#x660E;&#x5316;&#x5B66;&#x5408;&#x6210;&#x65B0;&#x65B9;&#x6CD5;&#x65B0;&#x7684;&#x4F20;&#x67D3;&#x6027;&#x75BE;&#x75C5;&#x6CBB;&#x7597;&#x5B66;&#x7684;&#x6F5C;&#x5728;&#x6765;&#x6E90;&#xFF0C;&#x786E;&#x5B9A;&#x53D1;&#x5C55;&#x6CBB;&#x7597;&#x6B63;&#x75D8;&#x75C5;&#x6BD2;&#x611F;&#x67D3;&#x8005;&#x53EF;&#x80FD;&#x6709;&#x5E0C;&#x671B;&#x7684;&#x5019;&#x9009;&#x4EBA;&#x3002;

&#x4ECE;&#x9762;&#x5411;&#x591A;&#x6837;&#x6027;&#x7684;&#x5408;&#x6210;&#x5E93; orthopoxviruses pyridopyrimidinone &#x6291;&#x5236;&#x5242;&#x7684;&#x6807;&#x8BC6;&#x3002;

Orthopoxviruses include the prototypical vaccinia virus, the emerging infectious agent monkeypox virus, and the potential biothreat variola virus (the causative agent of smallpox). There is currently no FDA-approved drug for humans infected with orthopoxviruses. We screened a diversity-oriented synthesis library for new scaffolds with activity against vaccinia virus. This screen identified a nonnucleoside analog that blocked postreplicative intermediate and late gene expression. Viral genome replication was unaffected, and inhibition could be elicited late in infection and persisted upon drug removal. Sequencing of drug-resistant viruses revealed mutations predicted to be on the periphery of the highly conserved viral RNA polymerase large subunit. Consistent with this, the compound had broad-spectrum activity against orthopoxviruses in vitro. These findings indicate that novel chemical synthesis approaches are a potential source for new infectious disease therapeutics and identify a potentially promising candidate for development to treat orthopoxvirus-infected individuals.

Identification of a pyridopyrimidinone inhibitor of orthopoxviruses from a diversity-oriented synthesis library.

Orthopoxvirus comprennent le virus prototype de la vaccine, le virus infectieux &#xE9;mergents monkeypox agent, et le potentiel de bioterrorisme virus variolique (l&#x26;#39;agent causal de la variole). Il n&#x26;#39;existe actuellement aucun m&#xE9;dicament approuv&#xE9; par la FDA pour les humains infect&#xE9;s par orthopoxvirus. Nous avons cribl&#xE9; une biblioth&#xE8;que orient&#xE9;e vers la diversit&#xE9; de synth&#xE8;se pour les &#xE9;chafaudages de nouvelles ayant une activit&#xE9; contre le virus de la vaccine. Cet &#xE9;cran a identifi&#xE9; un analogue non nucl&#xE9;osidique qui a bloqu&#xE9; l&#x26;#39;expression des g&#xE8;nes postr&#xE9;plicative interm&#xE9;diaire et tardive. La r&#xE9;plication du g&#xE9;nome viral n&#x26;#39;a pas &#xE9;t&#xE9; affect&#xE9;e, et l&#x26;#39;inhibition pourrait &#xEA;tre obtenue &#xE0; la fin de l&#x26;#39;infection et a persist&#xE9; lors du retrait des m&#xE9;dicaments. S&#xE9;quen&#xE7;age de virus r&#xE9;sistant aux m&#xE9;dicaments r&#xE9;v&#xE9;l&#xE9; des mutations pr&#xE9;vu pour &#xEA;tre sur la p&#xE9;riph&#xE9;rie de la sous-unit&#xE9; hautement conserv&#xE9;e ARN polym&#xE9;rase virale &#xE0; grande. Conform&#xE9;ment &#xE0; cela, le compos&#xE9; a une activit&#xE9; &#xE0; large spectre contre les orthopoxvirus in vitro. Ces r&#xE9;sultats indiquent que de nouvelles approches de synth&#xE8;se chimique sont une source potentielle de nouvelles th&#xE9;rapies des maladies infectieuses et d&#x26;#39;identifier un candidat potentiellement prometteuse pour le d&#xE9;veloppement pour traiter les personnes infect&#xE9;es par orthopoxvirus.

Identification d&#x26;#39;un inhibiteur de la Pyridopyrimidinone Orthopoxvirus partir d&#x26;#39;une biblioth&#xE8;que de synth&#xE8;se orient&#xE9;e vers la diversit&#xE9;

Orthopoxviruses geh&ouml;ren das prototypische Vaccinia-Virus, der aufstrebenden infekti&ouml;ses Agens Monkeypox Virus und die potenziellen Biothreat Variola-Virus (der Erreger der Pocken). Es gibt derzeit kein FDA zugelassene Medikament f&uuml;r Menschen, die mit Orthopoxviruses infiziert. Wir sehen eine Vielfalt-orientierte Synthese-Bibliothek f&uuml;r neue Ger&uuml;ste mit Aktivit&auml;t gegen des Vaccinia Virus. Dieser Bildschirm identifiziert eine analoge Nonnucleoside, die postreplicative zwischen- und sp&auml;ten Genexpression blockiert. Virale Genom-Replikation nicht betroffen war, und Hemmung l&ouml;ste in der Infektion und nach der Droge Entfernung beibehalten werden konnte. Sequenzierung von Medikamenten-resistenten Viren offenbart Mutationen, die voraussichtlich am Ortsrand der gro&szlig;en stark konservierten virale RNA-Polymerase-Untereinheit. Folgerichtig hatte das Compound Breitspektrum Aktivit&auml;t gegen Orthopoxviruses in-vitro. Diese Befunde zeigen, dass neuartige chemische Synthese Ans&auml;tze eine potenzielle Quelle f&uuml;r neue Infektionskrankheiten-Therapeutika sind und identifizieren einen potenziell vielversprechenden Kandidaten f&uuml;r die Entwicklung Orthopoxvirus-infizierten Personen zu behandeln.

Kennung f&uuml;r ein Pyridopyrimidinone-Inhibitor der Orthopoxviruses aus einer Vielfalt-orientierte Synthese-Bibliothek.

Orthopoxviruses includono il virus di vaccinia virus prototipo, il virus di vaiolo delle scimmie agente infettivo emergenti e i potenziali virus variola biothreat (l&#39;agente eziologico del vaiolo). Non esiste attualmente nessun farmaco approvato dalla FDA per gli esseri umani infettati con orthopoxviruses. Abbiamo proiettato una libreria sintesi orientato alla diversit&agrave; per ponteggi nuovi con attivit&agrave; contro il virus del vaiolo vaccino. Questo schermo identificato un analogico nonnucleoside che ha bloccato l&#39;espressione del gene postreplicative intermedia e tardiva. Replicazione del genoma virale &egrave; stato influenzato e inibizione potrebbe essere suscitato nel tardo infezione e persistenti dopo l&#39;espianto di droga. Sequenziamento del virus resistenti ai farmaci ha rivelato le mutazioni per essere alla periferia della subunit&agrave; grande polimerasi del RNA virale altamente conservata. Coerentemente con questo, il composto aveva attivit&agrave; ad ampio spettro contro orthopoxviruses in vitro. Questi risultati indicano che la sintesi chimica nuovi approcci sono una potenziale fonte per nuove terapie di malattie infettive e identificano un candidato potenzialmente promettente per lo sviluppo per trattare gli individui infettati orthopoxvirus.

Identificazione di un inibitore di pyridopyrimidinone di orthopoxviruses da una libreria di sintesi orientato alla diversit&agrave;.

Orthopoxviruses&#x306F;&#x3001;&#x5178;&#x578B;&#x7684;&#x30EF;&#x30AF;&#x30B7;&#x30CB;&#x30A2;&#x30A6;&#x30A4;&#x30EB;&#x30B9;&#x3001;&#x65B0;&#x8208;&#x611F;&#x67D3;&#x30A8;&#x30FC;&#x30B8;&#x30A7;&#x30F3;&#x30C8;&#x30B5;&#x30EB;&#x75D8;&#x30A6;&#x30A4;&#x30EB;&#x30B9;&#x3001;&#x304A;&#x3088;&#x3073;&#x6F5C;&#x5728;&#x7684;&#x306A;biothreat&#x75D8;&#x7621;&#x30A6;&#x30A4;&#x30EB;&#x30B9;&#xFF08;&#x5929;&#x7136;&#x75D8;&#x306E;&#x75C5;&#x539F;&#x4F53;&#xFF09;&#x304C;&#x542B;&#x307E;&#x308C;&#x3066;&#x3044;&#x307E;&#x3059;&#x3002; orthopoxviruses&#x306B;&#x611F;&#x67D3;&#x3057;&#x305F;&#x4EBA;&#x9593;&#x306E;&#x305F;&#x3081;&#x306E;FDA&#x627F;&#x8A8D;&#x85AC;&#x306F;&#x73FE;&#x5728;&#x3042;&#x200B;&#x200B;&#x308A;&#x307E;&#x305B;&#x3093;&#x3002;&#x6211;&#x3005;&#x306F;&#x3001;&#x30EF;&#x30AF;&#x30B7;&#x30CB;&#x30A2;&#x30A6;&#x30A4;&#x30EB;&#x30B9;&#x306B;&#x5BFE;&#x3059;&#x308B;&#x6D3B;&#x6027;&#x3092;&#x6301;&#x3064;&#x65B0;&#x3057;&#x3044;&#x8DB3;&#x5834;&#x306E;&#x305F;&#x3081;&#x306B;&#x591A;&#x69D8;&#x6027;&#x6307;&#x5411;&#x5408;&#x6210;&#x30E9;&#x30A4;&#x30D6;&#x30E9;&#x30EA;&#x30FC;&#x3092;&#x30B9;&#x30AF;&#x30EA;&#x30FC;&#x30CB;&#x30F3;&#x30B0;&#x3057;&#x305F;&#x3002;&#x3053;&#x306E;&#x753B;&#x9762;&#x3067;&#x306F;&#x3001;postreplicative&#x4E2D;&#x9593;&#x3068;&#x5F8C;&#x671F;&#x907A;&#x4F1D;&#x5B50;&#x306E;&#x767A;&#x73FE;&#x3092;&#x30D6;&#x30ED;&#x30C3;&#x30AF;&#x3059;&#x308B;&#x975E;&#x30CC;&#x30AF;&#x30EC;&#x30AA;&#x30B7;&#x30C9;&#x30A2;&#x30CA;&#x30ED;&#x30B0;&#x3092;&#x540C;&#x5B9A;&#x3057;&#x305F;&#x3002;&#x30A6;&#x30A4;&#x30EB;&#x30B9;&#x30B2;&#x30CE;&#x30E0;&#x306E;&#x8907;&#x88FD;&#x306B;&#x306F;&#x5F71;&#x97FF;&#x3057;&#x307E;&#x305B;&#x3093;&#x3067;&#x3057;&#x305F;&#x3057;&#x3001;&#x963B;&#x5BB3;&#x306F;&#x611F;&#x67D3;&#x306E;&#x5F8C;&#x671F;&#x306B;&#x8A98;&#x767A;&#x3057;&#x3001;&#x85AC;&#x7269;&#x9664;&#x53BB;&#x306B;&#x6C38;&#x7D9A;&#x5316;&#x3055;&#x308C;&#x308B;&#x53EF;&#x80FD;&#x6027;&#x304C;&#x3042;&#x308A;&#x307E;&#x3059;&#x3002;&#x85AC;&#x5264;&#x8010;&#x6027;&#x30A6;&#x30A4;&#x30EB;&#x30B9;&#x306E;&#x30B7;&#x30FC;&#x30AF;&#x30A8;&#x30F3;&#x30B9;&#x306F;&#x3001;&#x7A81;&#x7136;&#x5909;&#x7570;&#x306F;&#x9AD8;&#x5EA6;&#x306B;&#x4FDD;&#x5B58;&#x3055;&#x308C;&#x305F;&#x30A6;&#x30A4;&#x30EB;&#x30B9;RNA&#x30DD;&#x30EA;&#x30E1;&#x30E9;&#x30FC;&#x30BC;&#x306E;&#x5927;&#x30B5;&#x30D6;&#x30E6;&#x30CB;&#x30C3;&#x30C8;&#x306E;&#x5468;&#x56F2;&#x306B;&#x3042;&#x308B;&#x3068;&#x4E88;&#x6E2C;&#x3092;&#x660E;&#x3089;&#x304B;&#x306B;&#x3057;&#x305F;&#x3002;&#x3053;&#x308C;&#x3067;&#x3001;&#x4E00;&#x8CAB;&#x6027;&#x306E;&#x3042;&#x308B;&#x5316;&#x5408;&#x7269;&#x306F;in vitro&#x3067;orthopoxviruses&#x306B;&#x5BFE;&#x3059;&#x308B;&#x5E83;&#x57DF;&#x30B9;&#x30DA;&#x30AF;&#x30C8;&#x30EB;&#x6D3B;&#x6027;&#x3092;&#x6709;&#x3057;&#x3066;&#x3044;&#x305F;&#x3002;&#x3053;&#x308C;&#x3089;&#x306E;&#x77E5;&#x898B;&#x306F;&#x3001;&#x65B0;&#x898F;&#x306E;&#x5316;&#x5B66;&#x5408;&#x6210;&#x306E;&#x30A2;&#x30D7;&#x30ED;&#x30FC;&#x30C1;&#x306F;&#x3001;&#x65B0;&#x3057;&#x3044;&#x611F;&#x67D3;&#x75C7;&#x6CBB;&#x7642;&#x85AC;&#x306E;&#x6F5C;&#x5728;&#x7684;&#x306A;&#x6E90;&#x3067;&#x3042;&#x308A;&#x3001;&#x30AA;&#x30EB;&#x30BD;&#x611F;&#x67D3;&#x8005;&#x3092;&#x6CBB;&#x7642;&#x3059;&#x308B;&#x305F;&#x3081;&#x306E;&#x958B;&#x767A;&#x306E;&#x305F;&#x3081;&#x306E;&#x6F5C;&#x5728;&#x7684;&#x306B;&#x6709;&#x671B;&#x306A;&#x5019;&#x88DC;&#x3092;&#x7279;&#x5B9A;&#x3059;&#x308B;&#x3053;&#x3068;&#x3092;&#x793A;&#x3057;&#x3066;&#x3044;&#x307E;&#x3059;&#x3002;

&#x591A;&#x69D8;&#x6027;&#x6307;&#x5411;&#x5408;&#x6210;&#x30E9;&#x30A4;&#x30D6;&#x30E9;&#x30EA;&#x304B;&#x3089;Orthopoxviruses&#x306E;Pyridopyrimidinone&#x963B;&#x5BB3;&#x5264;&#x306E;&#x540C;&#x5B9A;

Orthopoxviruses&#xB294; &#xC6D0;&#xD615; vaccinia &#xBC14;&#xC774;&#xB7EC;&#xC2A4;, &#xC2E0;&#xD765; &#xC804;&#xC5FC;&#xC131;&#xC774; &#xC5D0;&#xC774;&#xC804;&#xD2B8; monkeypox &#xBC14;&#xC774;&#xB7EC;&#xC2A4; &#xC7A0;&#xC7AC;&#xC801;&#xC778; biothreat variola &#xBC14;&#xC774;&#xB7EC;&#xC2A4; (&#xCC9C;&#xC5F0;&#xB450;&#xC758; &#xC6D0;&#xC778;&#xC774; &#xC5D0;&#xC774;&#xC804;&#xD2B8;) &#xB4F1;&#xC774; &#xC788;&#xC2B5;&#xB2C8;&#xB2E4;. &#xD604;&#xC7AC; orthopoxviruses&#xC5D0; &#xAC10;&#xC5FC; &#xC778; &#xAC04;&#xC5D0; &#xB300; &#xD55C; &#xC544;&#xBB34; FDA &#xC2B9;&#xC778; &#xB41C; &#xC57D;&#xBB3C;&#xC774; &#xC774;&#xB2E4;. &#xC6B0;&#xB9AC; vaccinia &#xBC14;&#xC774;&#xB7EC;&#xC2A4;&#xC5D0; &#xB300; &#xD55C; &#xD65C;&#xB3D9;&#xC73C;&#xB85C; &#xC0C8;&#xB85C;&#xC6B4; &#xAC74;&#xC124; &#xAE30;&#xACC4; &#xC784;&#xB300;&#xC5D0; &#xB300; &#xD55C; &#xB2E4;&#xC591;&#xC131; &#xC911;&#xC2EC; &#xD569;&#xC131; &#xB77C;&#xC774;&#xBE0C;&#xB7EC;&#xB9AC;&#xB97C; &#xC0C1;&#xC601;. &#xC774; &#xD654;&#xBA74; postreplicative &#xC911;&#xAE09; &#xBC0F; &#xB2A6;&#xC740; &#xC720;&#xC804;&#xC790; &#xBC1C;&#xD604;&#xC744; &#xCC28;&#xB2E8; &#xD558;&#xB294; nonnucleoside &#xC544;&#xB0A0;&#xB85C;&#xADF8;&#xB97C; &#xC2DD;&#xBCC4; &#xD569;&#xB2C8;&#xB2E4;. &#xBC14;&#xC774;&#xB7EC;&#xC2A4; &#xC131; &#xAC8C;&#xB188; &#xBCF5;&#xC81C;&#xB294; &#xC601;&#xD5A5;&#xC744; &#xBC1B;&#xB294;, &#xADF8;&#xB9AC;&#xACE0; &#xC800;&#xD574; &#xAC10;&#xC5FC;&#xC5D0; &#xB2A6;&#xAC8C; elicited &#xC218; &#xC788;&#xACE0; &#xC57D;&#xBB3C; &#xC81C;&#xAC70;&#xC5D0; &#xB530;&#xB77C; &#xC9C0;&#xC18D;. &#xC57D;&#xBB3C; &#xB0B4;&#xC131; &#xBC14;&#xC774;&#xB7EC;&#xC2A4;&#xC758; &#xC2DC;&#xD000;&#xC2F1; &#xACF5;&#xAC1C; &#xBCC0;&#xC774; &#xB9E4;&#xC6B0; &#xBCF4;&#xC874;&#xB41C; &#xBC14;&#xC774;&#xB7EC;&#xC2A4; &#xC131; RNA &#xC911; &#xD569; &#xD6A8;&#xC18C; &#xD070; &#xC18C; &#xB2E8;&#xC704;&#xC758; &#xC8FC;&#xBCC0;&#xC5D0; &#xC788;&#xC744; &#xAC83;&#xC73C;&#xB85C; &#xC608;&#xC0C1; &#xD588;&#xB2E4;. &#xC774; &#xC77C;&#xAD00; &#xB41C; &#xD654;&#xD569;&#xBB3C; orthopoxviruses &#xCCB4; &#xC678;&#xC5D0; &#xB300; &#xD55C; &#xC2A4;&#xD399;&#xD2B8;&#xB7FC; &#xD65C;&#xB3D9;&#xC744; &#xD588;&#xB2E4;. &#xC774; &#xBC1C;&#xACAC;&#xC740; &#xC18C;&#xC124; &#xD654;&#xD559; &#xD569;&#xC131; &#xBC29;&#xBC95; &#xC0C8;&#xB85C;&#xC6B4; &#xC804;&#xC5FC; &#xC131; &#xC9C8;&#xD658; &#xCE58;&#xB8CC;&#xC81C;&#xC5D0; &#xB300; &#xD55C; &#xC7A0;&#xC7AC;&#xC801;&#xC778; &#xC18C;&#xC2A4; orthopoxvirus&#xC5D0; &#xAC10;&#xC5FC; &#xB41C; &#xAC1C;&#xC778; &#xCE58;&#xB8CC; &#xAC1C;&#xBC1C;&#xC5D0; &#xB300; &#xD55C; &#xC7A0;&#xC7AC;&#xC801;&#xC73C;&#xB85C; &#xC720;&#xB9DD;&#xD55C; &#xD6C4;&#xBCF4;&#xB97C; &#xC2DD;&#xBCC4; &#xB098;&#xD0C0;&#xB0C5;&#xB2C8;&#xB2E4;.

&#xB2E4;&#xC591;&#xC131; &#xC911;&#xC2EC; &#xD569;&#xC131; &#xB77C;&#xC774;&#xBE0C;&#xB7EC;&#xB9AC;&#xC5D0;&#xC11C; orthopoxviruses&#xC758; pyridopyrimidinone &#xC5B5;&#xC81C;&#xC81C;&#xC758; &#xC2DD;&#xBCC4;.

Ortopoxvirus son el prototipo de virus de la vacuna, el virus emergente agente infeccioso viruela de los monos, y el potencial biothreat virus de la viruela (el agente causante de la viruela). No hay actualmente ning&#xFA;n f&#xE1;rmaco aprobado por la FDA para los seres humanos infectados con ortopoxvirus. Hemos examinado una diversidad biblioteca orientada a la s&#xED;ntesis de nuevos andamios con actividad contra el virus vaccinia. En esta pantalla se identific&#xF3; un an&#xE1;logo no nucle&#xF3;sido que bloqueaba la expresi&#xF3;n de genes posreplicativo intermedia y tard&#xED;a. La replicaci&#xF3;n del genoma viral no se vio afectada, y la inhibici&#xF3;n puede ser obtenido a finales de la infecci&#xF3;n y persisten en la eliminaci&#xF3;n del f&#xE1;rmaco. La secuenciaci&#xF3;n de f&#xE1;rmaco-resistentes virus revel&#xF3; mutaciones prev&#xE9; que sea en la periferia de la altamente conservadas subunidad ARN polimerasa viral de gran tama&#xF1;o. Consistente con esto, el compuesto tiene actividad de amplio espectro contra ortopoxvirus in vitro. Estos hallazgos indican que los nuevos enfoques de s&#xED;ntesis qu&#xED;mica son una fuente potencial de nuevas terapias en enfermedades infecciosas e identificar a un candidato potencialmente prometedor para el desarrollo para el tratamiento de las personas infectadas por ortopoxvirus.

La identificaci&#xF3;n de un inhibidor de la Pyridopyrimidinone ortopoxvirus de una biblioteca de s&#xED;ntesis orientada a la Diversidad

Toll-like receptor 4 (TLR4) is activated by bacterial endotoxin, a prototypical pathogen-associated molecular pattern (PAMP). It has been suggested that TLR4 can also be activated by damage-associated molecular pattern (DAMP) proteins such as HSP70. It remains a challenge to provide unequivocal evidence that DAMP proteins themselves play a role in TLR4 activation, as the DAMP proteins used are often contaminated with endotoxin and other TLR ligands introduced during protein expression and/or purification.

Stimulation of TLR4 by recombinant HSP70 requires structural integrity of the HSP70 protein itself.

Myxoma virus (MYXV) and vaccinia virus (VACV), two distinct members of the family Poxviridae, are both currently being developed as oncolytic virotherapeutic agents. Recent studies have demonstrated that ex vivo treatment with MYXV can selectively recognize and kill contaminating cancerous cells from autologous bone marrow transplants without perturbing the engraftment of normal CD34(+) hematopoietic stem and progenitor cells. However, the mechanism(s) by which MYXV specifically recognizes and eliminates the cancer cells in the autografts is not understood. While little is known about the cellular attachment factor(s) exploited by MYXV for entry into any target cells, VACV has been shown to utilize cell surface glycosaminoglycans such as heparan sulfate (HS), the extracellular matrix protein laminin, and/or integrin β1. We have constructed MYXV and VACV virions tagged with the Venus fluorescent protein and compared their characteristics of binding to various human cancer cell lines as well as to primary human leukocytes. We report that the binding of MYXV or VACV to some adherent cell lines could be partially inhibited by heparin, but laminin blocked only VACV binding. In contrast to cultured fibroblasts, the binding of MYXV and VACV to a wide spectrum of primary human leukocytes could not be competed by either HS or laminin. Additionally, MYXV and VACV exhibited very different binding characteristics against certain select human leukocytes, suggesting that the two poxviruses utilize different cell surface determinants for the attachment to these cells. These results indicate that VACV and MYXV can exhibit very different oncolytic tropisms against some cancerous human leukocytes.

Myxoma and vaccinia viruses bind differentially to human leukocytes.

The genus Orthopoxviridae contains a diverse group of human pathogens including monkeypox, smallpox and vaccinia. These viruses are presumed to be less dependent on host functions than other DNA viruses because they have large genomes and replicate in the cytoplasm, but a detailed understanding of the host factors required by orthopoxviruses is lacking. To address this topic, we performed an unbiased, genome-wide pooled RNAi screen targeting over 17,000 human genes to identify the host factors that support orthopoxvirus infection. We used secondary and tertiary assays to validate our screen results. One of the strongest hits was heat shock factor 1 (HSF1), the ancient master regulator of the cytoprotective heat-shock response. In investigating the behavior of HSF1 during vaccinia infection, we found that HSF1 was phosphorylated, translocated to the nucleus, and increased transcription of HSF1 target genes. Activation of HSF1 was supportive for virus replication, as RNAi knockdown and HSF1 small molecule inhibition prevented orthopoxvirus infection. Consistent with its role as a transcriptional activator, inhibition of several HSF1 targets also blocked vaccinia virus replication. These data show that orthopoxviruses co-opt host transcriptional responses for their own benefit, thereby effectively extending their functional genome to include genes residing within the host DNA. The dependence on HSF1 and its chaperone network offers multiple opportunities for antiviral drug development.

The master regulator of the cellular stress response (HSF1) is critical for orthopoxvirus infection.

IRAK4 is a central kinase in innate immunity, but the role of its kinase activity is controversial. The mechanism of activation for IRAK4 is currently unknown, and little is known about the role of IRAK4 kinase in cytokine production, particularly in different human cell types. We show IRAK4 autophosphorylation occurs by an intermolecular reaction and that autophosphorylation is required for full catalytic activity of the kinase. Phosphorylation of any two of the residues Thr-342, Thr-345, and Ser-346 is required for full activity, and the death domain regulates the activation of IRAK4. Using antibodies against activated IRAK4, we demonstrate that IRAK4 becomes phosphorylated in human cells following stimulation by IL-1R and Toll-like receptor agonists, which can be blocked pharmacologically by a dual inhibitor of IRAK4 and IRAK1. Interestingly, in dermal fibroblasts, although complete inhibition of IRAK4 kinase activity does not inhibit IL-1-induced IL-6 production, NF-κB, or MAPK activation, there is complete ablation of these processes in IRAK4-deficient cells. In contrast, the inhibition of IRAK kinase activity in primary human monocytes reduces R848-induced IL-6 production with minimal effect on NF-κB or MAPK activation. Taken together, these studies define the mechanism of IRAK4 activation and highlight the differential role of IRAK4 kinase activity in different human cell types as well as the distinct roles IRAK4 scaffolding and kinase functions play.

Interleukin 1/Toll-like Receptor-induced Autophosphorylation Activates Interleukin 1 Receptor-associated Kinase 4 and Controls Cytokine Induction in a Cell Type-specific Manner.

Ken Dower

Department of Microbiology

Boston University School of Medicine

Vaccinia Reporter Viruses for Quantifying Viral Function at All Stages of Gene Expression

Ken Dower

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Department of Microbiology

Boston University School of Medicine

Vaccinia Reporter Viruses for Quantifying Viral Function at All Stages of Gene Expression

Department of Microbiology